Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study

Carlo Antozzi, Tuan Vu, Sindhu Ramchandren, Richard J Nowak, Constantine Farmakidis, Vera Bril, Jan De Bleecker, Huan Yang, Eduard Minks, Jin-Sung Park, Mariusz Grudniak, Marek Smilowski, Teresa Sevilla, Sarah Hoffmann, Kumaraswamy Sivakumar, Yasushi Suzuki, Eriene Youssef, Panna Sanga, Keith Karcher, Yaowei Zhu, John J Sheehan, Hong Sun

Open source

DOI: 10.1016/s1474-4422(24)00498-8
Published: 2025-02
Container: The Lancet Neurology
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1474-4422-24-00498-8,
  title = {Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study},
  author = {Carlo Antozzi and Tuan Vu and Sindhu Ramchandren and Richard J Nowak and Constantine Farmakidis and Vera Bril and Jan De Bleecker and Huan Yang and Eduard Minks and Jin-Sung Park and Mariusz Grudniak and Marek Smilowski and Teresa Sevilla and Sarah Hoffmann and Kumaraswamy Sivakumar and Yasushi Suzuki and Eriene Youssef and Panna Sanga and Keith Karcher and Yaowei Zhu and John J Sheehan and Hong Sun},
  year = {2025},
  journal = {The Lancet Neurology},
  doi = {10.1016/s1474-4422(24)00498-8},
  url = {https://doi.org/10.1016/s1474-4422(24)00498-8}
}

RIS

TY  - JOUR
TI  - Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study
AU  - Carlo Antozzi
AU  - Tuan Vu
AU  - Sindhu Ramchandren
AU  - Richard J Nowak
AU  - Constantine Farmakidis
AU  - Vera Bril
AU  - Jan De Bleecker
AU  - Huan Yang
AU  - Eduard Minks
AU  - Jin-Sung Park
AU  - Mariusz Grudniak
AU  - Marek Smilowski
AU  - Teresa Sevilla
AU  - Sarah Hoffmann
AU  - Kumaraswamy Sivakumar
AU  - Yasushi Suzuki
AU  - Eriene Youssef
AU  - Panna Sanga
AU  - Keith Karcher
AU  - Yaowei Zhu
AU  - John J Sheehan
AU  - Hong Sun
PY  - 2025
JO  - The Lancet Neurology
DO  - 10.1016/s1474-4422(24)00498-8
UR  - https://doi.org/10.1016/s1474-4422(24)00498-8
ER  -

APA

Antozzi, C., Vu, T., Ramchandren, S., Nowak, R. J., Farmakidis, C., Bril, V., Bleecker, J. D., Yang, H., Minks, E., Park, J., Grudniak, M., Smilowski, M., Sevilla, T., Hoffmann, S., Sivakumar, K., Suzuki, Y., Youssef, E., Sanga, P., Karcher, K., Zhu, Y., Sheehan, J. J., & Sun, H. (2025). Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(24)00498-8

Source records

crossref · retrieved 2026-09-26T21:56:20.788Z